Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2, Issue 12
June 26 2018
Issue Cover

Table of Contents

DRUG ADVANCES

The use of defibrotide in blood and marrow transplantation
Clinical Trials & Observations
Paul G. Richardson,Enric Carreras,Massimo Iacobelli,Bijan Nejadnik
View Articletitled, The use of defibrotide in blood and marrow transplantation

EXCEPTIONAL CASE REPORTS

Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor
Clinical Trials & Observations
Ioannis Politikos,Malgorzata McMasters,Christine Bryke,David Avigan,Vassiliki A. Boussiotis
View Articletitled, Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor
Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL
Clinical Trials & Observations
Matthias Wölfl,Mareike Rasche,Matthias Eyrich,Renate Schmid,Dirk Reinhardt,Paul G. Schlegel
View Articletitled, Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in <em>MLL</em>-rearranged infant ALL

STIMULUS REPORT

NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation
Louise E. Hogan,Christian Körner,Kristen Hobbs,Camille R. Simoneau,Cassandra Thanh,Erica A. Gibson,Christine D. Palmer,Alisha Pandit,Francisco M. Marty,Daniel R. Kuritzkes,Stephanie Jost,Jerome Ritz,Timothy J. Henrich
View Articletitled, NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation

REVIEW ARTICLE

The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective
Clinical Trials & Observations
James N. George
View Articletitled, The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective

CLINICAL TRIALS AND OBSERVATIONS

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis
Clinical Trials & Observations
Samuel Yamshon,Paul J. Christos,Michelle Demetres,Hoda Hammad,John P. Leonard,Jia Ruan
View Articletitled, Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis
Supplemental data
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001
Clinical Trials & Observations
Lynda M. Vrooman,Traci M. Blonquist,Marian H. Harris,Kristen E. Stevenson,Andrew E. Place,Sarah K. Hunt,Jane E. O’Brien,Barbara L. Asselin,Uma H. Athale,Luis A. Clavell,Peter D. Cole,Kara M. Kelly,Caroline Laverdiere,Jean-Marie Leclerc,Bruno Michon,Marshall A. Schorin,Maria Luisa Sulis,Jennifer J. G. Welch,Donna S. Neuberg,Stephen E. Sallan,Lewis B. Silverman
View Articletitled, Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001
Supplemental data

LYMPHOID NEOPLASIA

Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
Clinical Trials & Observations
Kristina Drott,Hans Hagberg,Karin Papworth,Thomas Relander,Mats Jerkeman
View Articletitled, Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
Supplemental data
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling
Clinical Trials & Observations
Vernon Wu,Erin Moshier,Siyang Leng,Bart Barlogie,Hearn Jay Cho,Sundar Jagannath,Deepu Madduri,Madhu Mazumdar,Samir Parekh,Ajai Chari
View Articletitled, Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling

MYELOID NEOPLASIA

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes
Clinical Trials & Observations
Abdullah Mahmood Ali,Yumin Huang,Ronald Feitosa Pinheiro,Fumin Xue,Jingping Hu,Nicholas Iverson,Daniela Hoehn,Diego Coutinho,Jehanzeb Kayani,Brian Chernak,Joseph Lane,Christopher Hillyer,Naomi Galili,Joseph Jurcic,Narla Mohandas,Xiuli An,Azra Raza
View Articletitled, Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes
Supplemental data
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarhan,Ludwig Brandt,Martin Felices,Karolin Guldevall,Todd Lenvik,Peter Hinderlie,Julie Curtsinger,Erica Warlick,Stephen R. Spellman,Bruce R. Blazar,Daniel J. Weisdorf,Sarah Cooley,Daniel A. Vallera,Björn Önfelt,Jeffrey S. Miller
View Articletitled, 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Supplemental data
Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice
Pingnan Xiao,Lakshmi Sandhow,Yaser Heshmati,Makoto Kondo,Thibault Bouderlique,Monika Dolinska,Anne-Sofie Johansson,Mikael Sigvardsson,Marja Ekblom,Julian Walfridsson,Hong Qian
View Articletitled, Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice
Supplemental data

THROMBOSIS AND HEMOSTASIS

Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014
Shannon L. Carpenter,Troy Richardson,Matt Hall
View Articletitled, Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014
Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets
Caterina Casari,David S. Paul,Sophie Susen,Cécile Lavenu-Bombled,Annie Harroche,Raymond Piatt,Kathryn O. Poe,Robert H. Lee,Marijke Bryckaert,Olivier D. Christophe,Peter J. Lenting,Cécile V. Denis,Wolfgang Bergmeier
View Articletitled, Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets
Supplemental data
Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice
Xuemei Fan,Conghui Wang,Panlai Shi,Wen Gao,Jianmin Gu,Yan Geng,Wenlong Yang,Ningbo Wu,Yang Wang,Yanyan Xu,Xue Chen,Lin Zhang,Kemin Wang,Bing Su,Junling Liu
View Articletitled, Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice
Supplemental data

TRANSFUSION MEDICINE

Blood group ABO gene–encoded A transferase catalyzes the biosynthesis of FORS1 antigen of FORS system upon Met69Thr/Ser substitution
Emili Cid,Miyako Yamamoto,Fumiichiro Yamamoto
View Articletitled, Blood group <em>ABO</em> gene–encoded A transferase catalyzes the biosynthesis of FORS1 antigen of FORS system upon Met69Thr/Ser substitution

COMMENTARY

BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?
Nina Rosa Neuendorff,Philipp Hemmati,Renate Arnold,Jana Ihlow,Bernd Dörken,Carsten Müller-Tidow,Jörg Westermann
View Articletitled, <em>BCR-ABL</em><sup>+</sup> acute myeloid leukemia: are we always dealing with a high-risk disease?
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Pappenheim staining of a bone marrow smear showing L1/L2 morphology of lymphoid leukemic blasts, reflecting relapse of infant acute lymphoblastic leukemia (original magnification ×500). See the article by Wölfl et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals